Pharmaxis Releases Promising Interim Data from Skin Scarring Study
26th
Sep 22
Release Date: 26/09/2022 8:52am
- Interim data from 8 patients treated with PXS-6302 shows a high level of inhibition of enzymes and changes in biomarkers that are implicated in scarring.
- Recruitment in the placebo controlled phase of the study has reached over 60% with full recruitment expected by year end and results in H1 2023.
- Pre-clinical data published in Nature Communications for the first time shows topically applied Pharmaxis pan-LOX inhibitors reduce collagen deposition and cross-linking and improve scar appearance without reducing tissue strength.
Categories: News and Media